胰腺导管腺癌的免疫治疗研究进展  

Research progress in immunotherapy for pancreatic ductal adenocarcinoma

作　　者：王蒲雄志 于新哲 史向军[1] 袁周[1] WANG Puxiongzhi;YU Xinzhe;SHI Xiangjun;YUAN Zhou(Department of Hepatobiliary and Pancreatic Surgery,the Affiliated Sixth People's Hospital,Shanghai Jiaotong University,Shanghai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院肝胆胰外科,上海200233

出　　处：《中国普通外科杂志》2021年第3期330-336,共7页China Journal of General Surgery

基　　金：上海市科学技术委员会科研计划资助项目(18ZR1429100)。

摘　　要：胰腺导管腺癌(PDAC)是常见的消化系统恶性肿瘤,恶性程度高,容易发生转移,手术切除率低。近年来,以程序性细胞死亡蛋白1/程序性死亡配体1(PD-1/PD-L1)抗体为代表的免疫检查点抑制剂在肿瘤的免疫治疗中取得了重大进展。然而,由于PDAC独特的肿瘤微环境及低免疫原性,PDAC的免疫治疗并不尽如人意。结合PDAC的微环境特点,笔者介绍免疫检查点抑制剂、过继细胞免疫以及肿瘤疫苗等在PDAC治疗中的进展和潜在的应用前景。Pancreatic ductal adenocarcinoma(PDAC)is a common malignant tumor of the digestive system,and characterized by a high degree of malignancy,high metastasis rate and low surgical resection rate.In recent years,significant progress has been made in tumor immunotherapy due to the application of immune checkpoint inhibitors that are represented by antibodies against programmed cell death protein 1/programmed death ligand 1(PD-1/PD-L1).However,owing to the unique tumor microenvironment and low immunogenicity of PDAC,the immunotherapy of PDAC is still unsatisfactory.Here,the authors,combined with the microenvironmental characteristics of PDAC,address the latest research advances in terms of immune checkpoint inhibitors,adoptive cellular immunity,and tumor vaccines in the treatment of PDAC,as well as their application prospects.

关 键 词：胰腺肿瘤 肿瘤微环境 免疫疗法 综述 

分 类 号：R735.9[医药卫生—肿瘤]